Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study.
KDIGO
Mimosa study
cinacalcet
compliance
secondary hyperparathyroidism
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
08
12
2018
entrez:
7
12
2019
pubmed:
7
12
2019
medline:
7
12
2019
Statut:
epublish
Résumé
Secondary hyperparathyroidism (SHPT) is frequent in haemodialysis (HD) patients. Oral cinacalcet-hydrochloride (HCl) decreases parathyroid hormone (PTH); however, real-life PTH data, according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, are still lacking. Our goal is to assess the percentage of cinacalcet-HCl-treated HD patients with controlled SHPT (PTH <9× upper limit of the normal range) after 12 months (M12) of treatment. This is a retrospective observational study in HD patients with SHPT treated by cinacalcet-HCl between 2005 and 2015 and dialysed in seven French HD centres using the same database (Hemodial™). The study included 1268 patients with a mean (standard deviation) follow-up of 21 ± 12 months. Their mean dialysis vintage was 4.3 ± 5.6 years. PTH values were available and exploitable at M12 in 50% of them (645 patients). Among these patients, 58.9% had controlled (mean PTH of 304 ± 158 pg/mL) and 41.1% uncontrolled SHPT (mean PTH of 1084 ± 543) at M12. At the baseline, patients with controlled SHPT were older (66 ± 15 versus 61 ± 17 years), and had lower PTH (831 ± 346 versus 1057 ± 480 pg/mL) and calcaemia (2.18 ± 0.2 versus 2.22 ± 0.19 mmol/L) than uncontrolled patients. In multivariate analysis, these three factors still remained significantly associated with controlled SHPT. In this real-life study, 41.1% of HD patients with SHPT treated with cinacalcet-HCl remained with a PTH above the KDIGO recommended target after 12 months of treatment. Apart from the possibility of non-compliance, the severity of SHPT appears to be a major factor determining the response to cinacalcet-HCl treatment, reinforcing the importance of treating SHPT at earlier stages.
Sections du résumé
BACKGROUND
BACKGROUND
Secondary hyperparathyroidism (SHPT) is frequent in haemodialysis (HD) patients. Oral cinacalcet-hydrochloride (HCl) decreases parathyroid hormone (PTH); however, real-life PTH data, according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, are still lacking. Our goal is to assess the percentage of cinacalcet-HCl-treated HD patients with controlled SHPT (PTH <9× upper limit of the normal range) after 12 months (M12) of treatment.
METHODS
METHODS
This is a retrospective observational study in HD patients with SHPT treated by cinacalcet-HCl between 2005 and 2015 and dialysed in seven French HD centres using the same database (Hemodial™).
RESULTS
RESULTS
The study included 1268 patients with a mean (standard deviation) follow-up of 21 ± 12 months. Their mean dialysis vintage was 4.3 ± 5.6 years. PTH values were available and exploitable at M12 in 50% of them (645 patients). Among these patients, 58.9% had controlled (mean PTH of 304 ± 158 pg/mL) and 41.1% uncontrolled SHPT (mean PTH of 1084 ± 543) at M12. At the baseline, patients with controlled SHPT were older (66 ± 15 versus 61 ± 17 years), and had lower PTH (831 ± 346 versus 1057 ± 480 pg/mL) and calcaemia (2.18 ± 0.2 versus 2.22 ± 0.19 mmol/L) than uncontrolled patients. In multivariate analysis, these three factors still remained significantly associated with controlled SHPT.
CONCLUSION
CONCLUSIONS
In this real-life study, 41.1% of HD patients with SHPT treated with cinacalcet-HCl remained with a PTH above the KDIGO recommended target after 12 months of treatment. Apart from the possibility of non-compliance, the severity of SHPT appears to be a major factor determining the response to cinacalcet-HCl treatment, reinforcing the importance of treating SHPT at earlier stages.
Identifiants
pubmed: 31807302
doi: 10.1093/ckj/sfz021
pii: sfz021
pmc: PMC6885690
doi:
Types de publication
Journal Article
Langues
eng
Pagination
871-879Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Nefrologia. 2016;36(2):164-75
pubmed: 26654696
Nephrol Dial Transplant. 2013 May;28(5):1241-54
pubmed: 23328710
Nephrol Dial Transplant. 2015 Jan;30(1):39-44
pubmed: 24516224
JAMA. 2017 Jan 10;317(2):146-155
pubmed: 28097355
Nephrol Dial Transplant. 2012 May;27(5):1942-9
pubmed: 21931122
Clin J Am Soc Nephrol. 2008 Jan;3(1):36-45
pubmed: 18178780
N Engl J Med. 2013 May 9;368(19):1844-5
pubmed: 23656653
Nephrol Ther. 2012 Dec;8(7):527-33
pubmed: 23018042
Kidney Int. 2003 Jul;64(1):254-62
pubmed: 12787417
Nephrol Ther. 2015 Apr;11(2):78-87
pubmed: 25457107
J Clin Invest. 1995 May;95(5):2047-53
pubmed: 7738171
Nephrol Dial Transplant. 2014 Oct;29(10):1815-20
pubmed: 24516228
Am J Kidney Dis. 2010 Sep;56(3):547-57
pubmed: 20430501
J Ren Nutr. 2006 Apr;16(2):87-99
pubmed: 16567265
Eur J Med Res. 2009 May 14;14(5):185-90
pubmed: 19541573
Eur J Clin Pharmacol. 2006 May;62(5):387-93
pubmed: 16604344
Clin J Am Soc Nephrol. 2008 Nov;3(6):1718-25
pubmed: 18945995
Nephrol Dial Transplant. 2011 Apr;26(4):1327-39
pubmed: 21148030
Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1031-40
pubmed: 25904755
Ther Apher Dial. 2010 Dec;14(6):577-82
pubmed: 21118366
Kidney Int Suppl. 2003 Jun;(85):S91-6
pubmed: 12753275
BMC Nephrol. 2013 Jul 18;14:153
pubmed: 23865421
Kidney Int Suppl. 2009 Aug;(113):S1-130
pubmed: 19644521
Clin J Am Soc Nephrol. 2010 Dec;5(12):2305-14
pubmed: 20798251
N Engl J Med. 2012 Dec 27;367(26):2482-94
pubmed: 23121374
Nephrol Dial Transplant. 2009 Sep;24(9):2852-9
pubmed: 19369690
Kidney Int. 2017 Jul;92(1):26-36
pubmed: 28646995
Nephrol Ther. 2016 Jun;12(3):171-7
pubmed: 26822333